Home > Knowledge > Content
NTRK 1/2/3 gene fusion detection
- Dec 05, 2018 -

November 26, USA Time,Bayer and Loxo Oncology announced that the anti-cancer drug Larotinib(larotrectinib,trade name Vitrakvi) was officially launched in the United States.

Larotrectinib, a small molecule drug targeting NTRK fusion gene, may be the next model of "different cancers,same treatment“after the PD-1 monoclonal antibody drug,Keytruda(Pembrolizumab). 

A number of studies have recommended that use the multiple methods(FISH +NGS+PCR) to detect NTRK1/2/3 gene fusion to avoid missing detection of NTRK1/2/3 positive patients , losing treatment opportunities.